These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27590905)

  • 1. Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice.
    Spindler SR; Mote PL; Flegal JM
    Age (Dordr); 2016 Dec; 38(5-6):379-391. PubMed ID: 27590905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.
    Raasch W; Jöhren O; Schwartz S; Gieselberg A; Dominiak P
    J Hypertens; 2004 Mar; 22(3):611-8. PubMed ID: 15076168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination.
    Tsikouris JP; Cox CD; Simoni JS; Seifert CF; Peek MC; Meyerrose GE
    Coron Artery Dis; 2006 Aug; 17(5):439-45. PubMed ID: 16845252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin.
    Deska P; Nowicki M
    J Physiol Pharmacol; 2017 Feb; 68(1):133-138. PubMed ID: 28456777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
    Zoja C; Corna D; Rottoli D; Cattaneo D; Zanchi C; Tomasoni S; Abbate M; Remuzzi G
    Kidney Int; 2002 May; 61(5):1635-45. PubMed ID: 11967013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.
    Koh KK; Quon MJ; Han SH; Ahn JY; Jin DK; Kim HS; Kim DS; Shin EK
    Hypertension; 2005 Jun; 45(6):1088-93. PubMed ID: 15883229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat.
    Dupuis F; Vincent JM; Limiñana P; Chillon JM; Capdeville-Atkinson C; Atkinson J
    J Hypertens; 2010 Jul; 28(7):1566-73. PubMed ID: 20589978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.
    Gross O; Schulze-Lohoff E; Koepke ML; Beirowski B; Addicks K; Bloch W; Smyth N; Weber M
    Nephrol Dial Transplant; 2004 Jul; 19(7):1716-23. PubMed ID: 15128880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts.
    Mital S; Magneson A; Loke KE; Liao J; Forfia PR; Hintze TH
    J Cardiovasc Pharmacol; 2000 Aug; 36(2):248-54. PubMed ID: 10942168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats.
    Miesel A; Müller-Fielitz H; Jöhren O; Vogt FM; Raasch W
    Br J Pharmacol; 2012 Apr; 165(8):2721-35. PubMed ID: 22014027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.
    Müller P; Kazakov A; Semenov A; Jagoda P; Friedrich EB; Böhm M; Laufs U
    J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):87-93. PubMed ID: 22368266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein.
    Abdel-Zaher AO; Elkoussi AE; Abudahab LH; Elbakry MH; Elsayed EA
    Fundam Clin Pharmacol; 2012 Dec; 26(6):701-11. PubMed ID: 21913974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes.
    Koh KK; Quon MJ; Han SH; Ahn JY; Lee Y; Shin EK
    Atherosclerosis; 2007 Sep; 194(1):230-7. PubMed ID: 16965776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan on cardiac norepinephrine release: comparison between ischemic and nonischemic conditions.
    Richardt D; Wolfrum S; Büttner C; Schäfer U; Dendorfer A; Kurz T; Richardt G
    J Cardiovasc Pharmacol; 2002 Oct; 40(4):641-6. PubMed ID: 12352328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.
    Krikov M; Thone-Reineke C; Müller S; Villringer A; Unger T
    J Hypertens; 2008 Mar; 26(3):544-52. PubMed ID: 18300867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
    MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974331
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
    Grothusen C; Bley S; Selle T; Luchtefeld M; Grote K; Tietge UJ; Drexler H; Schieffer B
    Atherosclerosis; 2005 Sep; 182(1):57-69. PubMed ID: 16115475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New clinical concepts after the ONTARGET trial.
    Ruilope LM; Segura J; Zamorano JL
    Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):685-9. PubMed ID: 21714599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.